SCHEMBL3963258

SCHEMBL3963258

CN1CCN(CCCNc2nccc(-c3cc4ccc(Br)cc4s3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 3/20 0.46
HRH4 Q9H3N8 2/20 0.43
IKBKB O14920 2/20 0.42
CHUK O15111 2/20 0.42
IKBKG Q9Y6K9 2/20 0.42
CDK4 P11802 1/20 0.40
GSK3B P49841 1/20 0.40
FGFR1 P11362 4/20 0.39
SRC P12931 3/20 0.38
EGFR P00533 2/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
SLC6A2 P23975 1/20 0.36
HRH2 P25021 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969427 0.88 IKBKB (0.53) MKNK1HRH4IKBKBCHUKIKBKG
Hydrochloric Acid SCHEMBL3961561 0.87 IKBKB (0.52) MKNK1HRH4IKBKBCHUKIKBKG
SCHEMBL4075976 0.87 MKNK1 (0.45) MKNK1HRH4IKBKBCHUKIKBKG
Hydrochloric Acid SCHEMBL3962134 0.83 FGFR1 (0.40) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL3963789 0.83 FGFR1 (0.46) FGFR1SRCEGFRFGFR2FGFR4
Hydrochloric Acid SCHEMBL4075209 0.82 FGFR1 (0.45) FGFR1SRCEGFRFGFR2FGFR4
Hydrochloric Acid SCHEMBL3964587 0.81 JAK2 (0.41) MKNK1HRH4IKBKBCHUKIKBKG
SCHEMBL3971664 0.80 SRC (0.47) MKNK1HRH4IKBKBCHUKIKBKG
SCHEMBL3962260 0.79 IKBKB (0.50) MKNK1IKBKBCHUKIKBKGCDK4
SCHEMBL3961990 0.79 FGFR1 (0.49) MKNK1FGFR1SRCEGFRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG MKNK1 167/4885HRH4 3000/4885IKBKB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.